Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

BACKGROUND: For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma. METHODS: The GeDDiS trial was a rando...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Lancet Oncol
Κύριοι συγγραφείς: Seddon, Beatrice, Strauss, Sandra J, Whelan, Jeremy, Leahy, Michael, Woll, Penella J, Cowie, Fiona, Rothermundt, Christian, Wood, Zoe, Benson, Charlotte, Ali, Nasim, Marples, Maria, Veal, Gareth J, Jamieson, David, Küver, Katja, Tirabosco, Roberto, Forsyth, Sharon, Nash, Stephen, Dehbi, Hakim-Moulay, Beare, Sandy
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Lancet Pub. Group 2017
Θέματα:
Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622179/
https://ncbi.nlm.nih.gov/pubmed/28882536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30622-8
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια